Is Dot & Key as effective as La Roche-Posay sunscreen? Read this comparison guide and choose the best sunscreen brands to ...

Whenever I ask them for product recommendations — whether it’s the best retinol serum or the right sunscreen to wear on a ...

Today's announcement could potentially add to a string of bad tariff news that has cost Roche 10.9%, Lilly 14%, and AstraZeneca stock 14.4% over the past week. Still, it remains to be seen ...

DR. DHINGRA: I think I tend to stick with the basics, Cetaphil and CeraVe, and then my favorite personally, I like La Roche-Posay. I say if you want to go to the drugstore and feel a little bougie ...

WATERVILLE, Ohio — Waterville and the Ohio Department of Transportation have agreed to delay the project to remove the Roche de Boeuf Bridge over the Maumee River in Waterville, the city ...

Sarepta and Roche are hoping after the independent DMC review that it will be able to continue dosing in the three studies. Image credit: Shutterstock / Andrii Yalanskyi. Sarepta Therapeutics and ...

Sarepta and Roche paused multiple Elevidys trials in the EU at the EMA’s request. HC Wainwright upgraded Sarepta to Neutral but sees Elevidys sales falling by Q2 2025. China’s new tariffs just ...

Roche on Thurs­day shared ear­ly pos­i­tive re­sults for its Alzheimer’s can­di­date tron­tinemab, the lat­est round of da­ta in its sec­ond at­tempt to de­vel­op a drug … ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in ...

Credit: superbeststock / Shutterstock. At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results of prasinezumab in patients with ...

The holds only affect the enrollment and dosing of new patients; those who have already received the one-time treatment will still be monitored as researchers continue to collect data, Roche said. The ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability ...